Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H3HM
|
||||
| Former ID |
DAP000076
|
||||
| Drug Name |
Aripiprazole
|
||||
| Synonyms |
Abilify; Abilitat; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Discmelt; Pripiprazole; Abilify Discmelt; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; OPC 31; Opc 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; OPC-14597; OPC-31; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H27Cl2N3O2
|
||||
| InChI |
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
|
||||
| InChIKey |
CEUORZQYGODEFX-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 129722-12-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
582954, 7848227, 7978512, 8187059, 11528738, 12014488, 14759758, 15103350, 25819894, 26719891, 29215485, 29215486, 43118141, 46386763, 46505745, 49658671, 49666283, 49666418, 49681659, 49830718, 57314118, 77392862, 81042514, 81065479, 81092781, 85202210, 85209988, 89736075, 92307952, 92308408, 92308936, 92713933, 103307946, 104021727, 104321668, 117470150, 117868935, 118048569, 124365869, 124658892, 124799564, 125001911, 125339803, 126525334, 126592371, 126624438, 126655782, 126669992, 126728368, 127275956
|
||||
| ChEBI ID |
ChEBI:31236
|
||||
| SuperDrug ATC ID |
N05AX12
|
||||
| SuperDrug CAS ID |
cas=129722129
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl). 2009 Jul 30. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 34). | ||||
| REF 3 | Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.